Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Equity Average (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Equity Average data on record, last reported at $1.6 billion in Q4 2025.

  • For Q4 2025, Equity Average fell 15.75% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, down 15.75%, while the annual FY2025 figure was $1.9 billion, 4.76% down from the prior year.
  • Equity Average reached $1.6 billion in Q4 2025 per RVMD's latest filing, down from $1.7 billion in the prior quarter.
  • Across five years, Equity Average topped out at $2.2 billion in Q1 2025 and bottomed at $524.9 million in Q2 2022.
  • Average Equity Average over 5 years is $1.2 billion, with a median of $912.8 million recorded in 2023.
  • Peak YoY movement for Equity Average: soared 414.41% in 2021, then decreased 25.42% in 2022.
  • A 5-year view of Equity Average shows it stood at $620.4 million in 2021, then grew by 10.14% to $683.3 million in 2022, then surged by 94.91% to $1.3 billion in 2023, then skyrocketed by 43.84% to $1.9 billion in 2024, then decreased by 15.75% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $1.6 billion in Q4 2025, $1.7 billion in Q3 2025, and $2.0 billion in Q2 2025.